NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jun 20 04:00PM ET
0.3810
Dollar change
-0.0039
Percentage change
-1.01
%
IndexRUT P/E- EPS (ttm)-0.81 Insider Own10.50% Shs Outstand59.22M Perf Week0.21%
Market Cap22.56M Forward P/E- EPS next Y-0.51 Insider Trans0.00% Shs Float53.00M Perf Month16.12%
Enterprise Value-26.85M PEG- EPS next Q-0.22 Inst Own47.23% Short Float4.81% Perf Quarter37.05%
Income-47.99M P/S- EPS this Y8.28% Inst Trans-35.52% Short Ratio1.45 Perf Half Y-40.47%
Sales0.00M P/B0.48 EPS next Y28.61% ROA-50.20% Short Interest2.55M Perf YTD-32.28%
Book/sh0.79 P/C0.28 EPS next 5Y17.27% ROE-78.32% 52W Range0.22 - 3.28 Perf Year-87.19%
Cash/sh1.36 P/FCF- EPS past 3/5Y17.45% -25.69% ROIC-61.53% 52W High-88.38% Perf 3Y-72.79%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- 52W Low72.40% Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM21.15% Oper. Margin- Volatility1.11% 4.51% Perf 10Y-
Dividend Ex-Date- Quick Ratio19.40 Sales Y/Y TTM- Profit Margin- RSI (14)61.57 Recom2.75
Dividend Gr. 3/5Y- - Current Ratio19.40 EPS Q/Q-6.28% SMA2011.44% Beta1.46 Target Price0.39
Payout- Debt/Eq0.67 Sales Q/Q- SMA5012.46% Rel Volume0.33 Prev Close0.38
Employees34 LT Debt/Eq0.67 EarningsMay 15 BMO SMA200-25.82% Avg Volume1.76M Price0.38
IPOJun 25, 2021 Option/ShortYes / Yes EPS/Sales Surpr.-27.66% - Trades Volume584,990 Change-1.01%
Date Action Analyst Rating Change Price Target Change
Mar-24-25Downgrade Stephens Overweight → Equal-Weight $5 → $1
Mar-21-25Downgrade Piper Sandler Overweight → Neutral $0.70
Mar-21-25Downgrade Leerink Partners Outperform → Market Perform $1
Mar-21-25Downgrade Citizens JMP Mkt Outperform → Mkt Perform
Jan-03-25Initiated William Blair Outperform
May-31-24Initiated Piper Sandler Overweight $10
May-14-24Initiated Stephens Overweight $8
Mar-01-24Initiated JMP Securities Mkt Outperform $7
May-30-23Upgrade SVB Securities Market Perform → Outperform $5 → $8
Dec-23-21Initiated H.C. Wainwright Buy $12
Jun-09-25 08:00AM
May-15-25 07:30AM
May-14-25 06:29AM
May-09-25 12:41PM
08:06AM
01:25PM Loading…
May-07-25 01:25PM
11:55AM
Apr-25-25 01:00PM
Apr-18-25 06:44AM
Mar-25-25 04:30PM
Mar-21-25 01:03PM
12:01PM
Mar-20-25 09:09AM
08:00AM
Mar-06-25 04:30PM
07:30AM Loading…
Feb-25-25 07:30AM
Jan-15-25 10:10AM
Jan-13-25 07:30AM
Jan-07-25 09:35AM
Dec-18-24 07:30PM
Dec-12-24 07:30AM
Dec-05-24 07:30AM
Nov-26-24 07:30AM
Nov-06-24 07:30AM
Oct-10-24 12:00PM
Oct-09-24 01:02PM
Sep-24-24 07:31AM
Sep-23-24 07:30AM
Sep-03-24 07:30AM
Aug-07-24 07:12AM
07:10AM Loading…
Aug-06-24 07:10AM
07:00AM
Jun-27-24 07:30AM
May-27-24 06:35AM
May-14-24 07:53AM
May-07-24 07:30AM
May-06-24 02:06PM
May-02-24 01:54PM
07:30AM
Apr-11-24 06:40AM
Apr-08-24 04:30PM
Mar-28-24 01:15PM
Mar-07-24 01:54PM
Mar-06-24 02:51PM
07:30AM
Mar-05-24 06:00PM
04:50PM
Mar-04-24 07:30AM
Feb-28-24 07:30AM
Feb-23-24 09:17AM
Feb-22-24 07:30AM
Jan-22-24 07:30AM
Jan-09-24 10:25AM
Jan-05-24 07:30AM
Nov-22-23 07:30AM
Nov-02-23 09:40AM
07:30AM
Sep-05-23 07:30AM
Aug-16-23 07:30AM
Aug-03-23 07:30AM
Jul-13-23 08:00AM
Jun-08-23 10:41PM
04:01PM
Jun-03-23 09:00AM
May-19-23 06:54AM
May-15-23 07:30AM
Apr-26-23 04:05PM
Apr-17-23 10:15AM
Mar-23-23 09:40AM
Mar-14-23 04:30PM
Mar-09-23 07:30AM
Mar-01-23 07:00AM
Feb-08-23 07:00AM
Jan-09-23 07:30AM
Jan-06-23 08:15AM
Nov-30-22 07:30AM
Nov-03-22 07:30AM
Aug-12-22 09:30AM
Aug-04-22 07:30AM
Aug-03-22 08:00AM
Jul-28-22 08:50AM
08:45AM
Jul-14-22 08:45AM
Jun-01-22 07:30AM
May-26-22 05:05PM
08:27AM
May-25-22 07:30AM
May-05-22 07:30AM
Apr-27-22 10:05AM
Mar-24-22 01:12PM
Mar-14-22 07:00AM
Mar-03-22 07:30AM
Mar-01-22 07:00AM
Jan-10-22 07:00AM
Jan-06-22 08:00AM
Jan-05-22 08:00AM
Dec-16-21 09:14AM
Nov-18-21 08:00AM
Nov-12-21 07:30AM
Oct-20-21 07:00AM
Elevation Oncology, Inc. is a precision oncology company, which engages in the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. The firm's program is focused on patients with advanced solid tumors harboring an NRG1 fusion. The company was founded by Shawn M. Leland in 2019 and is headquartered in Boston, MA.